Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Viral load -25% Improvement Relative Risk c19hcq.org Komissarov et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 36 patients in Russia Worse viral load with HCQ (not stat. sig., p=0.45) Komissarov et al., medRxiv, doi:10.1101/2020.06.30.20143289 Favors HCQ Favors control
Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19
Komissarov et al., medRxiv, doi:10.1101/2020.06.30.20143289 (Preprint)
Komissarov et al., Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19, medRxiv, doi:10.1101/2020.06.30.20143289 (Preprint)
Jun 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small late stage (7-10 days post symptoms) study of nasal swab RNA with 12 control and 33 patients, showing no significant differences (significant reduction in viral load is seen in both groups).
The groups are not comparable, with significant differences seen between hospitalized and non-hospitalized patients. 9 of 10 hospitalized patients were in the HCQ group and only one in the control group. 2 additional control patients were added between the first and second version of this preprint (including the only hospitalized control patient).
risk of viral load, 25.0% higher, RR 1.25, p = 0.45, treatment 26, control 10.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Komissarov et al., 30 Jun 2020, retrospective, Russia, preprint, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.30.20143289; this version posted September 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19 Alexey Komissarov1,2, Ivan Molodtsov1,3, Oxana Ivanova1,2, Elena Maryukhnich1,2, Svetlana Kudryavtseva1, Alexey Mazus4, Evgeniy Nikonov5, Elena Vasilieva1,2* 1 Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, Moscow, Russia. 2 Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia. 3 N.F. Gamaleya Federal National Research Centre for Epidemiology and Microbiology, Moscow, Russia. 4 Moscow City Center for AIDS Prevention and Control, Moscow Department of Healthcare, Moscow, Russia. 5 Moscow Department of Healthcare, Moscow, Russia. Abstract Due to the constantly growing numbers of COVID-19 infections and death cases attempts were undertaken to find drugs with anti SARS-CoV-2 activity among ones already approved for other pathologies. In the framework of such attempts, in a number of in vitro, as well as in vivo, models it was shown that hydroxychloroquine (HCQ) has an effect against SARS-CoV-2. While there was not enough clinical data to support the use of HCQ, several countries including Russia have included HCQ in treatment protocols for infected patients and for prophylactic. Here, we evaluated the SARS-CoV-2 RNA in nasopharynx swabs from infected patients in mild conditions and compared the viral RNA load dynamics between patients receiving HCQ and control group without antiviral pharmacological therapy. We found statistically significant relationship between maximal RNA quantity and patients’ deteriorating medical conditions, as well as confirmed the arterial hypertension to be a risk factor for people with COVID-19. However, we showed that HCQ therapy neither shortened the viral shedding period nor reduced the virus RNA load. Keywords: COVID-19, SARS-CoV-2, hydroxychloroquine, quantitative PCR with reverse transcription, viral load *Corresponding author: Elena that Vasilieva, MD, PhD, Clinical City Hospital named after I.V. NOTE: This preprint reports new research has not been certified by peer review and should not be used to guide clinical practice. Davydovsky, 11 Yauzskaya Street, Moscow, Russia, 109240. E-mail: vasilievahelena@gmail.com medRxiv preprint doi: https://doi.org/10.1101/2020.06.30.20143289; this version posted September 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit